WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers

Rhea-AI Summary

WuXi STA has launched a new sterile lipid nanoparticle (LNP) formulation facility at its Wuxi city campus, aimed at meeting the rising demand for complex injection dosage forms. This facility enhances the company's parenteral formulation capabilities by integrating advanced technologies, improving drug-loading, particle size control, and encapsulation efficiency. WuXi STA's integrated platform provides comprehensive services from pre-formulation to commercial manufacturing, bolstered by its 12 global sites. The new facility is designed to support innovative drug development and delivery across various formats.

Positive

• New sterile LNP facility enhances formulation capabilities.
• Integrates advanced technologies for improved drug delivery efficiency.
• Supports a wide range of manufacturing scales from 10-50 L per batch.
• Complements existing oligonucleotide CRDMO services.
• Positioned to meet growing demand for advanced injection dosage forms.

Negative

• None.

SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosage forms, this new facility marks the company's fast-growing parenteral formulation capabilities and is yet another opportunity to enable customers as they develop and deliver better medicines for patients.

This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform, offering significant advantages in drug-loading, liposome particle size control, and encapsulation efficiency.  In addition, the modular design provides greater processing flexibility, enabling this platform to serve a wide range of manufacturing scales from 10-50 L per batch.

As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA's integrated drug product platform offers a full spectrum of services, including solid-state development, pre-formulation, formulation development, and clinical to commercial drug product manufacturing with a variety of drug delivery technologies, including a broad range of oral and injectable dosage forms. This new sterile LNP platform further expands our end-to-end capabilities.

WuXi STA has 12 sites across the U.S., Europe and Asia that offer a wide range of services and meet global regulatory standards. Together with other development and manufacturing sites, this new platform provides considerable synergy with the company's oligonucleotide CRDMO platform. The LNP delivery system is particularly advantageous in overcoming the bioavailability challenge of oligonucleotides and their conjugates.  

Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, commented, "We are pleased to support our partners with this state-of-the-art LNP facility to meet the growing demand for advanced injection dosage forms. We will continue to expand our CRDMO platform's capacity and capabilities to enable our partners to accelerate more innovative drugs to market for patients worldwide."

About WuXi STA

WuXi STA (stapharma.com), a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.

For more information, please visit: http://www.STApharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/wuxi-sta-opens-a-new-sterile-lipid-nanoparticle-formulation-facility-to-enhance-global-crdmo-services-for-customers-301621040.html

SOURCE WuXi AppTec

FAQ

What is the new facility opened by WuXi STA for?

The new facility is designed for sterile lipid nanoparticle (LNP) formulation development and manufacturing, addressing the demand for complex injection dosage forms.

Where is the new WuXi STA facility located?

The new facility is located at WuXi STA's campus in Wuxi city, China.

What are the capabilities of the new LNP facility?

The facility offers improved drug-loading, particle size control, and encapsulation efficiency, with flexible processing for various manufacturing scales.

How many global sites does WuXi STA operate?

WuXi STA operates 12 sites across the U.S., Europe, and Asia, providing a wide range of CRDMO services.

What impact does the new facility have on WuXi STA's services?

The facility expands WuXi STA's CRDMO capabilities, enabling enhanced support for innovative drug development and delivery.